On October 17, 2025, Climb Bio, Inc. announced new long-term follow-up clinical data for their drug budoprutug, showing effective control of proteinuria in four patients over three years without severe adverse events. This event is significant for investors as it highlights potential advancements in treatment for B-cell mediated diseases, but it also carries risks related to regulatory approvals and competition.